Shanghai Phrontline Biopharma Co. Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting HER2 (erbB2) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.